These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 19496211)

  • 1. Isentress equal to Sustiva in first line therapy.
    Proj Inf Perspect; 2009 Mar; (48):6-7. PubMed ID: 19496211
    [No Abstract]   [Full Text] [Related]  

  • 2. Report from the 2008 joint ICAAC/IDSA meeting. Raltegravir vs. efavirenz in treatment-naive patients.
    Sax PE
    AIDS Clin Care; 2008 Dec; 20(12):97. PubMed ID: 19274772
    [No Abstract]   [Full Text] [Related]  

  • 3. [Raltegravir - long lasting effectiveness, well tolerated and well combined].
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():30-1. PubMed ID: 23961651
    [No Abstract]   [Full Text] [Related]  

  • 4. Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects.
    Proj Inf Perspect; 2009 Mar; (48):6. PubMed ID: 19492458
    [No Abstract]   [Full Text] [Related]  

  • 5. Raltegravir phase III study data released.
    AIDS Patient Care STDS; 2008 Nov; 22(11):917. PubMed ID: 19043838
    [No Abstract]   [Full Text] [Related]  

  • 6. Study supports use of Isentress for first line treatment.
    Proj Inf Perspect; 2008 Dec; (47):9. PubMed ID: 19227560
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-HIV agents. Raltegravir (Isentress)--results after one year.
    TreatmentUpdate; 2007; 19(6):8-9. PubMed ID: 18041152
    [No Abstract]   [Full Text] [Related]  

  • 8. Raltegravir as effective as efavirenz in 144-week data.
    AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-HIV agents. Using maraviroc in first-line therapy.
    TreatmentUpdate; 2007; 19(6):5-6. PubMed ID: 18041149
    [No Abstract]   [Full Text] [Related]  

  • 10. Report from the 16th Conference on Retroviruses and Opportunistic Infections. SWITCHMRK: an avoidable raltegravir disaster.
    Albrecht H
    J Watch AIDS Clin Care; 2009 Apr; 21(4):30-1. PubMed ID: 19548330
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-HIV agents. Integrase inhibitor raltegravir makes its mark.
    TreatmentUpdate; 2007 Feb; 19(2):8-9. PubMed ID: 17447316
    [No Abstract]   [Full Text] [Related]  

  • 12. Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load.
    Papendorp SG; van den Berk GE
    AIDS; 2009 Mar; 23(6):739. PubMed ID: 19279447
    [No Abstract]   [Full Text] [Related]  

  • 13. Study explains Isentress' excellent resistance profile.
    Proj Inf Perspect; 2008 Dec; (47):3. PubMed ID: 19226674
    [No Abstract]   [Full Text] [Related]  

  • 14. Raltegravir treatment response in an HIV-2 infected patient: a case report.
    Garrett N; Xu L; Smit E; Ferns B; El-Gadi S; Anderson J
    AIDS; 2008 May; 22(9):1091-2. PubMed ID: 18520356
    [No Abstract]   [Full Text] [Related]  

  • 15. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isentress gets another good grade.
    Dalton P
    Proj Inf Perspect; 2008 Sep; (46):9. PubMed ID: 19043877
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute porphyria precipitated by efavirenz.
    Pavitt CW; Rampling T; Byrne R; Tyebally S; Reid T; Nelson M
    AIDS; 2015 May; 29(8):981-2. PubMed ID: 25909830
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy.
    Imaz A; Podzamczer D
    AIDS Rev; 2012; 14(4):268-78. PubMed ID: 23258301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [FDA approval of the first HIV anti-retroviral from DuPont-Pharma: SUSTIVA (efavirenz). SUSTIVA should be associated with other anti-retrovirals and could be considered a new alternative first line treatment].
    Allerg Immunol (Paris); 1998 Oct; 30(8):268-70. PubMed ID: 9846197
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.